Entresto and Creatinine renal clearance decreased - a phase IV clinical study of FDA data

Summary:

Creatinine renal clearance decreased is reported as a side effect among people who take Entresto (sacubitril; valsartan), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Dapagliflozin, and have Cardiac failure.

The phase IV clinical study analyzes which people have Creatinine renal clearance decreased when taking Entresto. It is created by eHealthMe based on reports of 126,188 people who have side effects when taking Entresto from the FDA, and is updated regularly.

What is Entresto?

Entresto has active ingredients of sacubitril; valsartan. eHealthMe is studying from 126,628 Entresto users. Check the latest studies of Entresto.

What is Creatinine renal clearance decreased?

Creatinine renal clearance decreased is found to be associated with 472 drugs and 712 conditions by eHealthMe. Check the latest studies of Creatinine renal clearance decreased.

On Jul, 19, 2026

126,188 people reported to have side effects when taking Entresto.
Among them, 33 people (0.03%) have Creatinine renal clearance decreased.

Could Entresto cause Creatinine renal clearance decreased?

Among these 33 people:

How long have people been on Entresto when they have Creatinine renal clearance decreased? *

What is the gender of people who have Creatinine renal clearance decreased when taking Entresto? *

female: 26.67 %
male: 73.33 %

What is the age of people who have Creatinine renal clearance decreased when taking Entresto? *

What are other drugs people take besides Entresto? *

What are other side effects people have besides Creatinine renal clearance decreased? *

Blood Creatinine Increased: 8 people, 24.24%
Hyperkalemia (damage to or disease of the kidney): 7 people, 21.21%
Acute Kidney Failure: 4 people, 12.12%
Nausea And Vomiting: 3 people, 9.09%
Cardiac Failure: 3 people, 9.09%
Hypotension (abnormally low blood pressure): 3 people, 9.09%
Hypokalemia (low potassium): 3 people, 9.09%
Diarrhea: 3 people, 9.09%
Glomerular Filtration Rate Decreased: 3 people, 9.09%
General Physical Health Deterioration (weak health status): 3 people, 9.09%

What are the existing conditions these people have? *

Cardiac Failure: 19 people, 57.58%
Cardiac Failure Chronic: 5 people, 15.15%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 9.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 9.09%
Insomnia (sleeplessness): 3 people, 9.09%
Type 2 Diabetes: 3 people, 9.09%
High Blood Cholesterol: 3 people, 9.09%
Diabetes: 2 people, 6.06%
Acute Myocardial Infarction (acute heart attack): 2 people, 6.06%
Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Entresto and have Creatinine renal clearance decreased?

- Check whether Creatinine renal clearance decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Entresto:

Entresto (126,628 reports)

Browse all side effects of Entresto:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Creatinine renal clearance decreased:

Creatinine renal clearance decreased (472 drugs)

Browse all the conditions that are associated with Creatinine renal clearance decreased:

Creatinine renal clearance decreased (712 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sacubitril; valsartan (the active ingredients of Entresto) and Entresto (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.